MedTech Advisory Board Member First- Transcatheter HFpEF Heart Pump

Heart failure treatment has advanced dramatically, yet for the millions of patients with Advanced Stage HFpEF (Heart Failure with Preserved Ejection Fraction), effective therapies that extend life remain unavailable. Pumpinheart fixes this.

Pumpinheart is developing the world’s first transcatheter, implantable ECG-gated diastolic heart pump, designed specifically for Advanced Stage HFpEF. Originating from research at the Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Pumpinheart represents a new category of minimally invasive mechanical circulatory support addressing the single greatest unmet need in cardiovascular disease.

Advanced Stage HFpEF affects approximately 50% of all advanced heart failure patients, many of whom suffer debilitating symptoms with limited treatment options. Existing therapies fail to effectively address elevated left atrial pressure during diastole, the core physiological driver of HFpEF.

Pumpinheart’s technology delivers targeted diastolic unloading designed to:

• Reduce left atrial pressure
• Improve cardiac filling
• Allow patients breathless at rest to breathe freely again
• Improve exercise tolerance and quality of life
• Extend life expectancy by many years

This breakthrough innovation is delivered via a minimally invasive outpatient cath-lab procedure, typically requiring only one overnight stay. Pumpinheart’s foundation is built on deep cardiovascular research, advanced simulation, and early feasibility studies, and the company is now preparing for expanded clinical validation and strategic partnerships across the U.S. and Europe.

Pumpinheart is expanding its high-impact Med Tech Advisory Board, bringing together leaders across medical devices, digital health, healthcare systems, commercialization, and cardiovascular innovation.

We are seeking experienced health tech executives, operators, and strategists to help guide the development, validation, and adoption of one of the first transcatheter devices purpose-built for HFpEF.

As a Med Tech Advisory Board Member, you will play a critical role in positioning Pumpinheart for clinical and commercial success ensuring that our technology, workflows, and market strategy align with the realities of modern healthcare systems, medtech adoption, and enterprise deployment.

• Integration of Pumpinheart’s device into cardiology, interventional cardiology, HF clinics, and cath-lab workflows
• Optimization of pathways for clinical trials, regulatory approval, and early commercial adoption
• Scalable deployment models for hospitals, health systems, and advanced heart-failure programs
• Go-to-market strategy, KOL engagement, and early adoption roadmaps
• Real-world evidence generation and long‑term clinical validation
• Strategic connections across cardiovascular centers, health systems, and medtech ecosystems

Advisors will receive early visibility into Pumpinheart’s current fundraising round, with the opportunity to participate alongside clinicians, medtech leaders, and institutional supporters.

• Advise on integration of Pumpinheart into HF, cardiology, and cath‑lab workflows
• Provide strategic input on clinical trial design, regulatory pathways, and endpoint selection
• Share insights on procedural workflow, device positioning, and clinical data requirements

• Introduce Pumpinheart to health systems, heart‑failure programs, interventional cardiology leaders, and medtech partners
• Support expansion across priority markets in the U.S. and E.U.
• Advise on health‑system engagement, payer strategy, and market rollout sequencing

• Offer feedback on device usability, clinician experience, and procedural efficiency
• Advise on patient selection, outcomes measurement, and adoption barriers
• Provide insight into pricing strategy, reimbursement pathways, and commercial differentiation

Clinical, engineering, or health‑system leadership background in cardiology, devices, or health tech is valued but not required.

We are especially interested in…